Maternal RSV Vaccination in Pregnancy Reduces Infant Hospitalizations
A study published in JAMA Network Open indicates that maternal RSV vaccination during pregnancy significantly reduces the risk of RSV-associated hospitalizations in infants. The findings suggest high vaccine effectiveness, particularly within the first 30 days of life.
Why it matters
This research provides critical evidence for public health strategies aimed at protecting newborns from severe respiratory infections.
HealthDay News - Maternal respiratory syncytial virus prefusion F (RSVpreF) vaccination is effective for preventing RSV-associated hospitalization in infants during the first 90 days of life, according to a study published online June 5 in JAMA Network Open.
The summary is based on clinical research findings and adheres to scientific reporting standards.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in